Substantial portion of early arrhythmia recurrence after catheter ablation for atrial fibrillation (AF) is considered to be due to irritability in left atrium (LA) from the ablation procedure. We sought to evaluate whether 90-day use of antiarrhythmic drug (AAD) following AF ablation could reduce the incidence of early arrhythmia recurrence and thereby promote reverse remodelling of LA, leading to improved long-term clinical outcomes.
Introduction
Catheter ablation is increasingly performed as a curative therapy for atrial fibrillation (AF), but the high rate of arrhythmia recurrence is a limitation of the procedure. 1 -4 Although the major cause of recurrent atrial tachyarrhythmias following AF ablation is considered to be electrical reconnection of pulmonary veins (PVs), a sizable portion of early recurrence is considered to be due to irritability in left atrium (LA) from the ablation procedure. Indeed, previous studies have shown that 30% of patients with early recurrence had no further recurrent arrhythmias following the first couple of months post ablation. 5, 6 At the same time, early arrhythmia recurrence has been shown to be a strong predictor of late arrhythmia recurrence. 6 -8 Thus, short-term use of antiarrhythmic drugs (AADs) after ablation has been proposed as adjunctive approach not only to prevent early arrhythmia recurrence, but also to improve long-term outcomes by promoting reverse remodelling of LA through maintenance of sinus rhythm during the first several months after ablation. 7 -10 However, previous randomized controlled trials that enrolled only 100 -200 patients lacked statistical power to determine the effect of short-term AAD therapy on suppression of late arrhythmia recurrence.
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Accordingly, we conducted a large-scale multicentre prospective randomized controlled trial, evaluating the efficacy of 90-day use of AAD after catheter ablation for AF.
Methods
The Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial is a physician-initiated, non-company-sponsored, multicentre prospective randomized controlled trial, comparing 90-day use of AAD and control in patients who had undergone successful catheter ablation for AF. This study was a component of the 2 × 2 factorial randomized controlled trial, Kansai Plus Atrial Fibrillation trial. The other component was the UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate (UNDER-ATP) trial, evaluating the efficacy of adenosine triphosphate (ATP)-guided PV isolation (PVI) for AF. The trial was registered with ClinicalTrials.gov (NCT01477983). The study protocol was approved by the Institutional Review Board at each participating centre. Written informed consent was obtained from all the study patients.
Study population
Patients were recruited from 19 cardiovascular centres mostly located in the Kansai region of Japan (Supplementary material online, Appendix S1). Patients who were 21-79 years old undergoing first-time radiofrequency catheter ablation for paroxysmal, persistent, or long-lasting AF were eligible for the study. Exclusion criteria were contraindication or intolerance to ATP or Vaughan Williams class I or III AADs including severe asthma, severe vasospastic angina and substantial bradycardia, renal insufficiency (serum creatinine ≥2.0 mg/dL or on haemodialysis), New York Heart Association class IV heart failure, left ventricular ejection fraction ,40%, LA diameter .55 mm, very long-lasting (≥5 years) AF, intolerance for optimal anticoagulation, myocardial infarction within the past 6 months, prior or planned open heart surgery, severe valvular heart disease, inability to be followed at the outpatient clinic for 1 year, unwillingness to sign the consent form for participation, and patients whom the attending physician considered inappropriate to enrol in the study. Between November 2011 and March 2014, a total of 3722 patients were screened. Among 2120 patients initially enrolled in the trial, 76 patients were excluded after the ablation procedure because of severe procedural complications, substantial bradycardia, or some other reasons ( Figure 1) . Randomization was performed immediately after the ablation procedure, which was stratified by age (,70 or ≥70 years), gender, centre, type of AF, and preceding ablation procedure (ATP-guided or conventional PVI). 
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Ablation procedure
Vaughan Williams class I or III AADs were usually discontinued 5 halflives before the ablation procedure except amiodarone, which was encouraged to be discontinued at least 1 month before the procedure. The details of the ablation procedure were described in Supplementary material online. In brief, most patients underwent extensive encircling PVI, broadly isolating ipsilateral superior and inferior PVs simultaneously, with the use of irrigation catheter and a three-dimensional mapping system (CARTO, Biosense-Webster, Diamond Bar, CA, USA, or Ensite NavX, St Jude Medical, St Paul, MN, USA). The electrophysiological endpoint of PVI was bidirectional conduction block between LA and PVs. Approximately half of the patients underwent ATP-guided PVI ( Table 1) . Whether to perform additional ablation including tricuspid valve isthmus ablation, continuous fractionated atrial electrogram (CFAE) ablation, and LA linear ablation was left to the discretion of the operator and/or the attending physician.
Antiarrhythmic drug therapy
In patients assigned to 90-day use of AADs, Vaughan Williams class I or III AAD was started on the day of the ablation procedure. The choice and dosage of AADs were to be determined according to the Japanese AF guidelines 11, 12 and the reimbursement approval in Japan. The initial doses or standard maintenance doses of AADs approved by the reimbursement were 150 mg/day for pilsicainide, 100 mg/day for flecainide, 300 mg/day for cibenzoline, 450 mg/day for propafenone, 300 mg/day for disopyramide, 40 mg/day for aprindine, 100 mg/day for bepridil, 200 mg/day for amiodarone, and 80 mg/day for sotalol. Usage of amiodarone for AF was approved only in patients with heart failure, reduced left ventricular function, and/or hypertrophic cardiomyopathy. Sotalol was approved only for ventricular tachyarrhythmias. Neither dronedarone nor dofetilide was commercially available. For safety reason, the actual choice and dosage of the AADs were left to the discretion of the attending physician.
Definitions and endpoints
Paroxysmal AF was defined as that terminates spontaneously or under AADs within 7 days of onset. Persistent AF was defined as that lasting for more than 7 days up to 1 year and long-lasting AF was defined as that lasting for more than 1 year. Higher-and lower-volume centres were defined as those performing first-time ablation for AF of ≥100 cases/year and ,100 cases/year, respectively, during the patient enrolment period. The primary endpoint of the study was recurrent atrial tachyarrhythmias at 1 year excluding the events during the treatment (blanking) period of 90 days post ablation. The definitions of recurrent atrial tachyarrhythmias were those lasting for .30 s or requiring repeat ablation, hospital admission, or usage of Vaughan Williams class I or III AADs. Repeat ablation during the blanking period of 90 days was strongly discouraged. When repeat ablation was performed within 90 days post ablation, the patient was considered as having recurrent atrial tachyarrhythmias within 90 days and also having those at Day 91. The secondary efficacy endpoints were recurrent atrial tachyarrhythmias during the treatment period of 90 days and repeat ablation for any atrial tachyarrhythmia at 1 year. In patients assigned to the AAD group, usage of class I or III AAD during the treatment period of 90 days was not considered as the clinical event. The secondary safety endpoints were the side effects of AADs.
Follow-up
Patients were scheduled to receive periodical follow-up at the outpatient clinic of the centres in which the index ablation was performed at 3, 6, and 12 months. The time window for each visit was 77 -105 days for 3 months, 150 -240 days for 6 months, and 330 -450 days for 12 months. Twelve-lead electrocardiogram was obtained at every visit. One-channel electrocardiograms were recorded for a duration of 2 weeks, twice daily, and when patient had symptoms, at hospital discharge, 6 months, and 12 months with the use of ambulatory electrogram recorder (HCG-801, OMRON HEALTHCARE Co., Ltd). Twenty-four hour Holter monitoring was performed at 6 and 12 months. Ambulatory electrocardiograms were read by cardiologists at the core laboratory who were unaware of the treatment assignments. Records of Holter monitoring were read by clinicians at the local centre. When patients became unable to visit the outpatient clinic of the local centre, the follow-up data were obtained by contacting the physicians in-charge or the patients. All the clinical data were imputed by clinical research coordinators, clinicians, and/or attending physicians at the local centre. Experienced clinical research coordinators (Supplementary material online, Appendix S2) from the study management centre (Research Institute for Production Development, Kyoto, Japan) checked 10% of the imputed data, viewing the hospital charts and records.
Statistical analysis
The details of the sample size calculation are described in Supplementary material online. In brief, the treatment effect of the 90-day use of AAD on the primary endpoint was assumed to be 20% in relative risk reduction. Assuming the arrhythmia recurrence rate in patients with paroxysmal AF to be 32% and that in patients with persistent or longlasting AF to be 60%, and also assuming the proportion of paroxysmal and persistent/long-lasting AF in the study population to be 3:1, 1840 patients were required to achieve 90% power to detect a significant difference with a two-sided alpha level of 0.05. Considering possible drop out of the patients, differences between the expected and actual rates of the primary endpoint, and differences between the expected and actual distributions of AF type, at least 2000 patients were to be enrolled in the study. Data are presented as values and percentages, mean value + SD, or median with first to third quartile (Q1-Q3). Categorical variables were compared with the x 2 test or Fisher's exact test. Continuous variables were compared using the Student's t-test or Wilcoxon rank-sum test on the basis of their distributions. Event-free rate was estimated by the Kaplan-Meier method, and differences were assessed by the log-rank test. All analyses regarding the primary and secondary endpoints comparing ATP-guided PVI and conventional PVI groups were performed by the intention-to-treat manner. Because the time window for 1-year followup was defined as 330 -450 days in the study protocol, the clinical events of up to 450 days were included in the analyses. Patients who died during follow-up and those who were lost to follow-up were censored at the date of death or last contact.
Because of the programming error in the randomization system to minimize the imbalance of allocation in each dichotomized age stratum, patients were oppositely allocated to the treatment group towards imbalance, which affected the distribution of other stratification variables and age-related baseline patient characteristics (Table 1) . However, we predetermined to use the Cox proportional hazard model to estimate the treatment effects of the 90-day use of AAD on the primary endpoint and secondary efficacy endpoints, adjusting for the stratification variables (age, gender, centre, type of AF, and ATP-guided PVI). The adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) are presented.
All analyses were conducted by two physicians (T.T and K.N.) and a statistician (T.M.) with the use of SAS 9.4 and JMP 10.0.2 (SAS Institute Inc., Cary, NC, USA). All the statistical analyses were two-tailed, and probability values of less than 0.05 were considered statistically significant. 
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Results
Patients
Between November 2011 and March 2014, a total of 2120 patients were initially enrolled in the study. After the ablation procedure, 76 patients were excluded because of severe procedural complications (N ¼ 23), substantial bradycardia (N ¼ 13), withdrawal of consent (N ¼ 7), or some other reasons (N ¼ 33). Randomization was performed immediately after the ablation procedure. Excluding 6 patients who withdrew consent to participate in the study during follow-up, 2038 patients were the population of the study (Figure 1) . The baseline patient characteristics are shown in Table 1 . Mean age was 63.3 + 10.0 years, and 1530 patients (75.1%) were male. A total of 1376 patients (67.5%) had paroxysmal AF. There were significant differences in age, gender, and age-related patient characteristics between the groups. Also, patients in the control group more often had received ATP-guided PVI. Adherence to 2-week electrocardiogram recording at hospital discharge, 6 months, and 12 months was 90.8, 73.6, and 61.2%, respectively, with no significant difference between the groups. Compliance with 24 h Holter monitoring at 6 and 12 months was 66.6 and 55.4%, respectively. Compliance with either 2-week electrocardiogram recording or 24 h Holter monitoring at 6 and 12 months was 87.4 and 76.1%, respectively, with no significant difference between the groups.
During the index hospitalization, 48 patients (4.7%) in the AAD group discontinued or did not start the AAD due to suspected side effects or substantial bradycardia identified for the first time after randomization. Fifty-seven patients (5.6%) in the control group started AADs because of highly symptomatic recurrent atrial tachyarrhythmias.
The details of the drugs in the AAD group are shown in Table 2 . Most frequently used AADs were pilsicainide and flecainide, followed by bepridil and cibenzoline.
Primary and secondary efficacy outcomes
At 1 year, five patients died and six patients were lost to follow-up ( Figure 1) . During the treatment period of 90 days, patients assigned to the AAD group were associated with significantly higher eventfree survival from recurrent atrial tachyarrhythmias when compared with the control group (59.0 vs. 52.1%, respectively; adjusted HR 0.84; 95% CI 0.73 -0.96; P ¼ 0.01) (Figure 2A) . However, after discontinuation of the AADs at 90 days, there was no significant difference in the event-free rates from the primary endpoint of recurrent atrial tachyarrhythmias between the two groups (adjusted HR 0.93; 95% CI 0.79 -1.09; P ¼ 0.38). The 1-year event-free rate from the primary endpoint was 69.5% in the AAD group and 67.8% in the control group ( Figure 2B) . Even when patients were divided into those with paroxysmal AF and those with persistent or long-lasting AF, no significant difference was observed in the event-free rates from the primary endpoint between the AAD and control groups (Supplementary material online, Figure S1 ). The pre-specified subgroup analyses regarding the treatment effect of the 90-day use of AAD on the primary endpoint are shown in Figure 3 . There was no significant interaction in all the subgroups.
Also, there was no significant difference between the groups in the event-free rates from repeat ablation for any atrial tachyarrhythmia during follow-up (83.4 and 82.4%, respectively; adjusted HR 0.91; 95% CI 0.74-1.13; P ¼ 0.39) ( Figure 2C ). Figure 4 shows the event-free survival from the primary endpoint of recurrent atrial tachyarrhythmias comparing patients with and without early arrhythmia recurrence within 90 days. Patients with early arrhythmia recurrence were associated with much lower event-free survival from late arrhythmia recurrence.
Adverse clinical outcomes
During the treatment period of 90 days, 77 patients (7.6%) in the AAD group and 146 patients (14.3%) in the control group had a crossed-over treatment. In the AAD group, 41 patients (4.1%) had side effects of the AADs requiring change or discontinuation of the drugs, although there was no severe adverse event due to the AADs. During the median follow-up of 387 (366 -450) days, there were 5 deaths (0.5%), including 1 sudden cardiac death (0.1%) in the control group. A total of 113 patients (11.1%) in the AAD group and 117 patients (11.5%) in the control group received cardioversion (P ¼ 0.82) ( Table 3) .
Discussion
The present randomized controlled trial evaluated the efficacy of 90-day use of AAD after catheter ablation for AF. Although a significant reduction of early arrhythmia recurrence during the treatment period of 90 days was observed, it did not lead to improved clinical outcomes at the later phase following discontinuation of the drug. Nevertheless, early arrhythmia recurrence was strongly associated with late arrhythmia recurrence.
The results of this study are in accordance with the previous small randomized controlled trials. In the Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study), 110 patients undergoing catheter ablation for paroxysmal AF were randomly assigned to 6-week use of AAD or no-treatment. Despite significant reduction in arrhythmia recurrence within 6 weeks, there was no difference in the arrhythmia-free rates at 6 months. 212 patients undergoing catheter ablation for paroxysmal or persistent AF were randomized to 8-week administration of amiodarone or placebo. Again, acute effect of amiodarone was observed, but discontinuation of the drug led to similar arrhythmia-free rates at 6 months. 9 In both studies, early arrhythmia recurrence during the treatment period was a strong predictor of late arrhythmia recurrence. The theoretical background of the hypothesis that suppressing early arrhythmia recurrence with AAD for a couple of months after catheter ablation for AF may promote reverse electrical remodelling of LA and thereby suppress late arrhythmia recurrence was derived from the study by Wijffels et al. in 1995. 13 They reported the progressive shortening of effective refractory period of atrium by induction of artificial AF in goats, proposing the concept of 'Atrial fibrillation begets atrial fibrillation'. Thereafter, Rostock et al. 14 reported this electrical remodelling of atrium in human subjects undergoing catheter ablation for left-sided accessory pathway. They showed that progressive shortening of effective refractory period by artificial AF was pronounced in PVs rather than atrium. Conversely, we hypothesized that maintenance of sinus rhythm with AADs in combination with catheter ablation may promote reverse electrical remodelling of the atrium and stabilize the heart towards stable sinus rhythm without arrhythmia recurrence. Unfortunately, however, the consistent results of the previous and present studies strongly suggest that LA and PVs in patients undergoing catheter ablation for AF are mostly so degenerated and arrhythmogenic to expect the reverse electrical remodelling within a duration of several months.
Although long-term use of AADs after AF ablation may be effective in reducing the risk of arrhythmia recurrence, the benefit of AADs may be offset by their side effects, especially in elderly patients or those with structural heart disease and/or heart failure. 15 -17 Indeed, in the recent report by Zhang et al., 18 a second ablation procedure was more effective in maintaining sinus rhythm than AADs in patients with arrhythmia recurrence after catheter ablation for persistent AF.
There are several important limitations in this study. First, as mentioned in Methods and Results, because of the programming error in the randomization system to minimize the imbalance of allocation in each dichotomized age stratum, patients were oppositely allocated to the treatment group towards imbalance. However, we used the Cox proportional hazards model to estimate the treatment effects of the 90-day use of AAD on the primary endpoint and secondary efficacy endpoints, adjusting for the stratification variables. Therefore, we think the estimated effects of the 90-day use of AAD on the primary endpoint and secondary efficacy endpoints were appropriately calculated. Indeed, we have confirmed that the difference in age did not affect the incidence of the primary endpoint (data not shown). Secondly, although patients received periodical assessment with the ambulatory electrogram recording and 24 hour Holter monitoring in this study, there may have been substantial undetected episodes of recurrent atrial tachyarrhythmia during follow-up. Thirdly, CFAE ablation was more frequently performed in the control group. Fourthly, the AADs used in this study were different from those recommended or actually used in Western countries. 19, 20 However, although cibenzoline and bepridil are rarely used in Western countries, both drugs have been shown to be highly effective in restoring and maintaining sinus rhythm in AF patients. 21 -24 Finally, the average doses of AADs used in the present study were lower than usual doses in Western countries, presumably because of the lower approved doses of AADs in Japan and the propensity of Japanese cardiologists to prefer lower doses of AADs to avoid severe side effects. 10, 25 However, given the significant reduction in early arrhythmia recurrence and the acceptable rate of side effects in the AAD group of the present study, and also considering the fact that the average body weight of Asian patients with AF is much lighter than that of Western AF patients by 20 kg, 26 the doses of AADs used in the present study might have been appropriate.
In conclusion, short-term use of AAD for 90 days following AF ablation reduced the incidence of recurrent atrial tachyarrhythmias during the treatment period, but it did not lead to improved clinical outcomes at the later phase. 
